NCT00847249View on ClinicalTrials.gov

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions

Healthy

Interventions

DRUG

AZD9164

Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

DRUG

Placebo

Each subject will receive a single-dose.

Trial Locations (1)

Unknown

Research Site, Lund